By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx Biopharma (HEB) Announces Financial Results For The Six Months Ended June 30, 2014 8/11/2014 7:45:33 AM
Hemispherx Biopharma (HEB)'s Two Drugs, Ampligen® And Alferon® Ranked Highly In Sensitivity Testing Against MERS/SARS Coronaviruses 8/4/2014 8:24:03 AM
Hemispherx Biopharma (HEB) Achieves High Ranking In Sensitivity Testing Against MERS/SARS Coronaviruses Compared To Other Drugs 7/22/2014 3:36:24 PM
Hemispherx Biopharma (HEB) And Bioclones, A Leading South African Biotechnology Company, Join Forces On Novel Therapeutic Cancer Vaccine 7/14/2014 7:58:45 AM
Hemispherx Biopharma (HEB) And Bioclones Join Forces In Effort To Eradicate HIV/AIDS Virus Based On Recent Clinical Insights Of Wistar Institute, University of Pennsylvania 7/8/2014 10:39:00 AM
Hemispherx Biopharma (HEB) To Present During The 2014 Biotechnology Industry Organization (BIO) International Convention June 26 6/25/2014 8:00:13 AM
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014 7:54:51 AM
Hemispherx Biopharma (HEB) Announces That The University of Texas Medical Branch Confirms Activity Of Alferon® N Against MERS (Middle East Respiratory Syndrome) Virus 6/4/2014 9:09:04 AM
Hemispherx Biopharma (HEB) Receives New U.S. Composition Of Matter Patent Covering Ampligen® Formulations 5/27/2014 8:58:23 AM
Hemispherx Biopharma (HEB) And GP Pharm Agree To Establish A Manufacturing Operation In Argentina To Serve Latin America Markets And Ancillary Markets 5/21/2014 9:25:30 AM